Aurobindo Pharma Limited: High Court Dismisses Writ Petition Related to SEBI Settlement Order
Aurobindo Pharma Limited has reported on a significant legal development, noting that the Hon'ble High Court of Telangana, Hyderabad, dismissed a writ petition filed by promoters and group members. The order, received on May 15, 2026, pertains to a settlement process initiated under SEBI regulations.The petitioners involved in the matter, including Mr. P. V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited, are all members of the company's promoter and promoter group.
The dispute originated when the petitioners filed a settlement application with the Securities and Exchange Board of India (SEBI) under the Settlement Regulations. This application concerned alleged violations of Regulations 3 and 4 read with Regulation 12(2) of the SEBI (Prohibition of Insider Trading) Regulations, 1992. SEBI subsequently passed a settlement order on May 6, 2020.
The matter escalated when SEBI issued an email on October 23, 2020, directing the petitioners to deposit profits, totaling Rs. 6.53 crores, along with interest at 12% per annum, into the Investor Protection and Education Fund. The petitioners subsequently challenged this directive by filing a writ petition before the Hon'ble High Court of Telangana, Hyderabad.
However, the High Court, in its order dated May 6, 2026, dismissed the Writ Petition. The petitioners have stated that they will decide on the future course of action in consultation with their legal advisors.
The key details regarding the judicial action and the company's stance are summarized below:
| Particulars | Details |
|---|---|
| Authority | Hon'ble High Court of Telangana, at Hyderabad |
| Nature of Action | Dismissal of Writ Petition (Order dated May 6, 2026) |
| Underlying Issue | Alleged violation of SEBI (Prohibition of Insider Trading) Regulations, 1992. |
| Previous SEBI Directive | Deposit of profits (Rs. 6.53 crores) plus interest @ 12% per annum into the Investor Protection and Education Fund. |
| Impact on Company | Since the Order is against the Petitioners, there is no impact on the Company's financials or operations. |
Aurobindo Pharma Limited confirmed that the order dated May 6, 2026, was received on May 15, 2026. The company noted that the action taken by the High Court does not affect its own operational or financial standing.
AUROPHARMA Stock Price Movement
On Friday, Aurobindo Pharma Limited shares slipped by 0.04% to close at ₹1511.8. Despite dipping sharply, the stock had previously hit an impressive 52-week high of ₹1528, with trading concluding on a volume of 707,047 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.